Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Differential morphological and functional features of fibroblasts explanted from solar lentigo.

Goorochurn R, Viennet C, Tissot M, Locatelli F, Granger C, Varin-Blank N, Humbert P, Le Roy C.

Br J Dermatol. 2017 Oct;177(4):e109-e111. doi: 10.1111/bjd.15386. Epub 2017 Sep 5. No abstract available.

PMID:
28211565
2.

Scleroderma Peripheral B Lymphocytes Secrete Interleukin-6 and Transforming Growth Factor β and Activate Fibroblasts.

Dumoitier N, Chaigne B, Régent A, Lofek S, Mhibik M, Dorfmüller P, Terrier B, London J, Bérezné A, Tamas N, Varin-Blank N, Mouthon L.

Arthritis Rheumatol. 2017 May;69(5):1078-1089. doi: 10.1002/art.40016.

3.

Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells.

Ah-Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin-Blank N, Fabre EE, Schischmanoff O.

J Cell Mol Med. 2016 Oct;20(10):1956-65. doi: 10.1111/jcmm.12887. Epub 2016 Jul 27.

4.

TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.

Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F.

Int J Cancer. 2016 Oct 15;139(8):1759-63. doi: 10.1002/ijc.30222. Epub 2016 Jun 24.

5.

Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.

Saint-Georges S, Quettier M, Bouyaba M, Le Coquil S, Laurienté V, Guittat L, Lévy V, Ajchenbaum-Cymbalista F, Varin-Blank N, Le Roy C, Ledoux D.

Oncotarget. 2016 Jul 5;7(27):41031-41046. doi: 10.18632/oncotarget.9031.

6.

Biological processes in solar lentigo: insights brought by experimental models.

Goorochurn R, Viennet C, Granger C, Fanian F, Varin-Blank N, Roy CL, Humbert P.

Exp Dermatol. 2016 Mar;25(3):174-7. doi: 10.1111/exd.12937. Review.

PMID:
26739821
7.

Mutation of Vav1 adaptor region reveals a new oncogenic activation.

Razanadrakoto L, Cormier F, Laurienté V, Dondi E, Gardano L, Katzav S, Guittat L, Varin-Blank N.

Oncotarget. 2015 Feb 10;6(4):2524-37.

8.

Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.

Bernard S, Danglade D, Gardano L, Laguillier C, Lazarian G, Roger C, Thieblemont C, Marzec J, Gribben J, Cymbalista F, Varin-Blank N, Ledoux D, Baran-Marszak F.

Int J Cancer. 2015 Jun 15;136(12):2761-74. doi: 10.1002/ijc.29326. Epub 2014 Dec 3.

9.

Old DAT and new data: positive direct antiglobulin test identifies a subgroup with poor outcome among chronic lymphocytic leukemia stage A patients.

Quinquenel A, Al Nawakil C, Baran-Marszak F, Eclache V, Letestu R, Khalloufi M, Boubaya M, Le Roy C, Varin-Blank N, Delmer A, Levy V, Ajchenbaum-Cymbalista F.

Am J Hematol. 2015 Jan;90(1):E5-8. doi: 10.1002/ajh.23861. Epub 2014 Oct 25.

10.

Munc18-2 and syntaxin 3 control distinct essential steps in mast cell degranulation.

Brochetta C, Suzuki R, Vita F, Soranzo MR, Claver J, Madjene LC, Attout T, Vitte J, Varin-Blank N, Zabucchi G, Rivera J, Blank U.

J Immunol. 2014 Jan 1;192(1):41-51. doi: 10.4049/jimmunol.1301277. Epub 2013 Dec 9.

Supplemental Content

Loading ...
Support Center